NCT05969665 Effect of Monitoring Continuous Glucose Levels and Physical Activity Via Wearables on Cardiovascular Risk Factors
| NCT ID | NCT05969665 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Basel, Switzerland |
| Condition | Coronary Heart Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-02-07 |
| Primary Completion | 2025-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2024-02-07 with a primary completion date of 2025-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aims to assess the effect of smart watches and continuous glucose measuring devices on cardiovascular risk factors.
Eligibility Criteria
Inclusion Criteria: * Informed Consent signed by the subject * Completed outpatient cardiac rehabilitation * Diagnosis of coronary heart disease * Access to a smartphone for the duration of the study * 18 years or older on the date of consent Exclusion Criteria: * Diseases which limit physical activity including angina with incomplete revascularisation, arrhythmogenic cardiomyopathy, stroke with residual disease, and major orthopaedic disorders * Known or suspected non-compliance * Inability to follow the procedures of the investigation, e.g., due to language problems, psychological disorders, dementia, etc. of the subject * Diabetic patients receiving insulin therapy * Lack of proficiency with smart phone/watch * Current participation in any other clinical trial, which may confound the results of this trial. * NYHA (New York Heart Association) class III or IV congestive heart failure * Pregnancy
Contact & Investigator
Jan Gerrit van der Stouwe, Dr. med.
PRINCIPAL INVESTIGATOR
University Hospital, Basel, Switzerland
Frequently Asked Questions
Who can join the NCT05969665 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Heart Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05969665 currently recruiting?
Yes, NCT05969665 is actively recruiting participants. Contact the research team at jangerrit.vanderstouwe@usb.ch for enrollment information.
Where is the NCT05969665 trial being conducted?
This trial is being conducted at Basel, Switzerland.
Who is sponsoring the NCT05969665 clinical trial?
NCT05969665 is sponsored by University Hospital, Basel, Switzerland. The principal investigator is Jan Gerrit van der Stouwe, Dr. med. at University Hospital, Basel, Switzerland. The trial plans to enroll 100 participants.